Thanks to a five-year, $780,000 grant awarded by Canadian Institutes of Health Research, our biotech spinout BLR Bio’s research collaboration with research partner Dr. Andy Leask from the University of Saskatchewan is another step closer to finding a new therapy for people with debilitating scleroderma.